Clinical Trial Update: UK ENcorafenib and BInimetinib Real-world Study in Melanoma

View source ↗

Summary

A real-world UK study of encorafenib and binimetinib in metastatic melanoma with a BRAF V600 mutation; the study status is ACTIVE_NOT_RECRUITING and sponsor is …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Binimetinib (binimetinib)
• Encorafenib (encorafenib)

Snippet

Sponsor: Pierre Fabre Ltd | Conditions: Metastatic Melanoma, BRAF V600 Mutation Positive | Status: ACTIVE_NOT_RECRUITING